PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.44 - 1.45
1.18 - 2.36
71.0K / 1.73M (Avg.)
-18.12 | -0.08
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-4.06%
Negative revenue growth while 1177.HK stands at 0.00%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-8.23%
Negative gross profit growth while 1177.HK is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
-22.68%
Negative EBIT growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-72.83%
Negative operating income growth while 1177.HK is at 0.00%. Joel Greenblatt would press for urgent turnaround measures.
-42.27%
Negative net income growth while 1177.HK stands at 0.00%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-42.34%
Negative EPS growth while 1177.HK is at 0.00%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-42.22%
Negative diluted EPS growth while 1177.HK is at 0.00%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.08%
Share change of 0.08% while 1177.HK is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.01%
Diluted share change of 0.01% while 1177.HK is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Dividend reduction while 1177.HK stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-63.88%
Negative OCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-80.46%
Negative FCF growth while 1177.HK is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
47013.22%
10Y revenue/share CAGR above 1.5x 1177.HK's 253.83%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
313.21%
5Y revenue/share CAGR above 1.5x 1177.HK's 53.69%. David Dodd would look for consistent product or market expansions fueling outperformance.
30.64%
3Y revenue/share CAGR above 1.5x 1177.HK's 19.97%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
159.90%
OCF/share CAGR of 159.90% while 1177.HK is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
185.52%
5Y OCF/share CAGR above 1.5x 1177.HK's 7.03%. David Dodd would confirm if the firm has better cost structures or brand premium boosting mid-term cash flow.
-62.94%
Negative 3Y OCF/share CAGR while 1177.HK stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
603.05%
Net income/share CAGR above 1.5x 1177.HK's 227.64% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
130.57%
5Y net income/share CAGR above 1.5x 1177.HK's 8.04%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
-57.34%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
0.64%
Below 50% of 1177.HK's 587.23%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
16.51%
Below 50% of 1177.HK's 50.83%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
7.76%
Positive short-term equity growth while 1177.HK is negative. John Neff sees a strong advantage in near-term net worth buildup.
-100.00%
Cut dividends over 10 years while 1177.HK stands at 689.54%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-7.95%
Inventory is declining while 1177.HK stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
180.97%
Asset growth of 180.97% while 1177.HK is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
No Data
No Data available this quarter, please select a different quarter.
-10.30%
We’re deleveraging while 1177.HK stands at 0.33%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
-100.00%
Our R&D shrinks while 1177.HK invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-5.33%
We cut SG&A while 1177.HK invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.